Know Labs (NYSE:KNW) announced today that it appointed a new chief science officer (CSO) and interim chief technology officer (CTO). The company picked Dominic Klyve to serve as CSO, while John Cronin takes up the interim CTO role. Seattle-based Know Labs develops non-invasive diagnostic technology, including a wearable continuous glucose monitor (CGM). The company unveiled […]
Know Labs
Know Labs data backs non-invasive sensor for glycemic status screening
Know Labs (NYSE:KNW) today shared new data highlighting the use of its non-invasive blood glucose sensor in glycemic status monitoring. The Seattle-based company published its peer-reviewed study in Diabetes Technology & Therapeutics Journal. The published results demonstrated that Know Labs’ proprietary non-invasive radiofrequency (RF) dielectric sensor and trade-secret machine learning (ML) algorithms correctly classified an individual’s glycemic […]
The biggest diabetes tech news out of ATTD 2024
Catch up on the latest in diabetes tech from Dexcom, Abbott, Roche Diabetes Care, Insulet, Medtronic and Know Labs. Every year, the diabetes community comes together for the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). In this year’s 17th installment, some of the biggest names shared new studies and technologies set to […]
Know Labs has positive accuracy data for non-invasive glucose monitor
Know Labs (NYSE:KNW) announced interim results highlighting the accuracy of its non-invasive glucose monitoring sensor. Seattle-based Know Labs conducted a study evaluating its proprietary radiofrequency (RF) dielectric sensor. The sensor non-invasively measured blood glucose in participants with prediabetes and type 2 diabetes. It used venous blood as a comparative reference. Know Labs reported a mean […]
Know Labs to raise up to $12M for non-invasive CGM tech
Know Labs (NYSE:KNW) announced that it entered into a funding agreement for an investment worth up to $12 million. The Seattle-based company executed a $4 million close as part of this investment with Lind Global Fund II. The Lind Partners, a New York-based institutional fund manager, manages Lind Global Fund II. Funding helps Know Labs […]
Know Labs unveils wearable, non-invasive CGM set for FDA submission
Know Labs (NYSE:KNW) today unveiled KnowU, its wearable, non-invasive continuous glucose monitor (CGM) system. Seattle-based Know Labs first announced its initial prototype last June. It says KnowU is the result of an accelerated development process over the past eight months. The system incorporates the sensor developed by the company that it plans to submit for […]
Know Labs prices $7M public offering
Know Labs (NYSE:KNW) announced today that it priced an underwritten public offering worth about $7 million in proceeds. Seattle-based Know Labs, which develops a non-invasive glucose monitor, is offering 28 million shares of common stock. It priced the offering at 25¢ per share, with aggregate gross proceeds expected to total $7 million. The company expects […]
Know Labs has more positive data for its non-invasive glucose monitor
Know Labs (NYSE:KNW) today announced results from a new study that further demonstrate the accuracy of its Bio-RFID sensor technology. Last month, the company unveiled the prototype for its proprietary non-invasive sensor technology. Its proprietary Bio-RFID technology uses spectroscopy to direct electromagnetic energy through a substance or material. Through this, it can capture a unique molecular signature. The […]
Know Labs unveils non-invasive glucose monitor prototype
Know Labs (NYSE:KNW) today unveiled the first-generation prototype of its non-invasive glucose monitoring technology. Seattle-based Know Labs incorporated its Bio-RFID sensor into the first generation of this technology. The proprietary Bio-RFID technology uses spectroscopy to direct electromagnetic energy through a substance or material. Through this, it can capture a unique molecular signature. The Know Labs technology integrates […]
Study supports feasibility of Know Labs non-invasive CGM
Know Labs (NYSE:KNW) today announced the results of a feasibility study comparing its glucose monitoring technology to the Dexcom G6 CGM. The company titled its study “Technical Feasibility of a Novel Sensor for Non-Invasive Blood Glucose Monitoring Compared to Dexcom G6.” It’s presenting results today at the American Association of Clinical Endocrinology (AACE) Annual Meeting in […]
